Eli Lilly and Co (NYSE:LLY)
| 140.83 Delayed Data As of Feb 19 |  -0.18 / -0.13%Today’s Change | 101.36 Today|||52-Week Range 147.87 | +7.15% Year-to-Date |
Latest LLY News | Press Releases
| Better Buy: Vertex Pharmaceuticals vs. Incyte Feb 19 / MotleyFool.com - Paid Partner Content | Will Eczema Drug Dupixent Transform Sanofi? Feb 13 / MotleyFool.com - Paid Partner Content |
| Is Viking Therapeutics' Stock a Buy? Feb 18 / MotleyFool.com - Paid Partner Content | Eli Lilly and Incyte Record Another Positive Clinical Trial for Olumiant Works in Eczema Feb 12 / MotleyFool.com - Paid Partner Content |
| Better Buy: AbbVie vs. Eli Lilly Feb 18 / MotleyFool.com - Paid Partner Content | A Double Failure of Alzheimer's Drugs Feb 10 / MotleyFool.com - Paid Partner Content |
| Could This Cancer Drug Developer’s Stock Make You Rich? Feb 14 / MotleyFool.com - Paid Partner Content | Stock Market News: Coronavirus Hits NIO; Lilly Suffers Alzheimer's Defeat Feb 10 / MotleyFool.com - Paid Partner Content |
| How Incyte Beat Wall Street Estimates in Q4 Feb 13 / MotleyFool.com - Paid Partner Content | 3 Canadian Biotechs to Consider Buying Today Feb 07 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 141.01 |
| Today’s open | 141.62 |
| Day’s range | 140.36 - 141.84 |
| Volume | 3,082,771 |
| Average volume (3 months) | 3,378,182 |
| Market cap | $135.4B |
Data as of 6:30pm ET, 02/19/2020
Growth & Valuation
| Earnings growth (last year) | -- |
| Earnings growth (this year) | +12.33% |
| Earnings growth (next 5 years) | +11.50% |
| Revenue growth (last year) | -- |
| P/E ratio | 31.3 |
| Price/Sales | 5.51 |
| Price/Book | -- |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| ABBVAbbVie | +0.53 | +0.57% |
| AZNAstraZeneca | +0.20 | +0.41% |
| SNYSanofi | -0.43 | -0.84% |
| NVONovo Nordisk | +0.05 | +0.08% |
Data as of 6:30pm ET, 02/19/2020
Financials
| Next reporting date | April 23, 2020 |
| EPS forecast (this quarter) | $1.44 |
| Annual revenue (last year) | $22.3B |
| Annual profit (last year) | $8.3B |
| Net profit margin | 20.78% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Indianapolis, Indiana |
Forecasts
